OncLive TV

Jonathan Mizrahi, MD, discusses the addition of veliparib to chemotherapy in BRCA1/2 or PALB2-mutated pancreatic cancer.

Ignace B. Vergote, MD, PhD, discusses the need to develop novel therapies in endometrial cancer.

Thomas Hope, MD, discusses the rationale for using 68Ga-PSMA-11 PET to detect pelvic nodal metastasis in men with intermediate- or high-risk prostate cancer.

Gareth J. Morgan, MD, PhD, discusses the evolution of treatment options in multiple myeloma.

Ursula A. Matulonis, MD, discusses final data from the phase 2 KEYNOTE-100 trial with pembrolizumab (Keytruda) in advanced recurrent ovarian cancer.

Ritu Salani, MD, discusses opportunities for precision medicine in cervical cancer.

James Weitzman, MD, medical oncologist, Emerson Hospital and Waltham Cancer Center of Massachusetts General Cancer Center, discusses sequencing challenges in multiple myeloma treatment.

Courtney DiNardo, MD, MSCE, iscusses findings from a pooled analysis examining venetoclax (Venclexta) combination treatment in acute myeloid leukemia.

Caron Jacobson, MD, discusses the benefit of axicabtagene ciloleucel (axi-cel; Yescarta) in patients with relapsed/refractory follicular lymphoma.

Fred Saad, MD, FRCS, discusses the randomized phase 3 SPARTAN trial in nonmetastatic castration-resistant prostate cancer.

Reem Karmali, MD, MS, discusses the importance of evaluating older patients with mantle cell lymphoma in the rituximab era.

Reem Karmali, MD, MS, discusses the importance of evaluating older patients with mantle cell lymphoma in the rituximab era.

Hun Ju Lee, MD, discusses early efficacy data from a phase 1b/2 study of the investigational ROR1 inhibitor cirmtuzumab in combination with ibrutinib in patients with relapsed/refractory mantle cell lymphoma.

Jamie E. Chaft, MD, discusses considerations for restarting immunotherapy in patients with lung cancer.

Michael Wang, MD, discusses the safety and effectiveness of the autologous anti-CD19 CAR T-cell therapy KTE-X19 in patients with higher- versus lower-risk mantle cell lymphoma.

William K. Kelly, DO, discusses results from a phase 1b dose-finding study evaluating the combination of radium-223 dichloride (Xofigo) plus niraparib (Zejula) in patients with metastatic castration-resistant prostate cancer.

Benjamin Leon Musher, MD, discusses immunotherapy versus TKIs in hepatocellular carcinoma.

Sara M. Tolaney, MD, MPH, discusses the unmet need with regard to effectively preventing central nervous system recurrence in HER2-positive breast cancer.

Javier Cortes, MD, PhD, discusses updated progression-free survival data from the phase 3 KEYNOTE-355 study with pembrolizumab plus chemotherapy in previously untreated patients with locally recurrent, inoperable or metastatic triple-negative breast cancer.

Ian W. Flinn, MD, PhD, discusses the role of BTK inhibitors in chronic lymphocytic leukemia.

Ian W. Flinn, MD, PhD, discusses the role of BTK inhibitors in chronic lymphocytic leukemia.

Naveen Pemmaraju, MD, discusses the challenges of targeting TP53-mutant myelodysplastic syndrome and acute myeloid leukemia.

Daniel Moreira, MD, discusses the rationale for launching the Global COVID-19 Observatory and Resource Center for Childhood Cancer.

Konstantin Zakashansky, MD, discusses repeat exposure to PARP inhibition in patients with platinum-sensitive, relapsed ovarian cancer.

Hun Ju Lee, MD, discusses the mechanism of action of the investigational ROR1 inhibitor cirmtuzumab in combination in mantle cell lymphoma and chronic lymphocytic leukemia.

Prithviraj Bose, MD, discusses management strategies for patients with myelofibrosis who progress on ruxolitinib (Jakafi).

Xiuning Le, MD, PhD, discusses the rationale for tepotinib in MET exon 14 skipping

Jia Ruan, MD, PhD, discusses stratifying risk in mantle cell lymphoma.

Sattva Neelapu, MD, discusses the mechanism of action of ALLO-501 when paired with ALLO-647 in patients with relapsed/refractory large B-cell lymphoma or follicular lymphoma.

Jia Ruan, MD, PhD, discusses stratifying risk in mantle cell lymphoma.